Image

Phase 3 Study of S-217622 in Prevention of Symptomatic SARS-CoV-2 Infection

Recruiting
years of age
Both
Phase 3

Powered by AI

Overview

The purpose of this study is to measure the proportion of participants who are infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (positive reverse transcription polymerase chain reaction [RT-PCR] test) and have coronavirus disease 2019 (COVID-19) symptom(s) with S-217622 tablets compared with placebo tablets in participants who are household contacts of an individual with symptomatic COVID-19.

Description

This study will enroll 2 types of participants: 1. those with a negative screening SARS-CoV-2 infection (referred to as "study participants"); 2. those with a positive screening SARS-CoV-2-infection (referred to as "index participants"). Study participants will receive study intervention (S-217622 or placebo), index participants will receive no study intervention.

Eligibility

Inclusion Criteria:

Index Participants

        Only 1 index participant from each household will be enrolled in the study. Participants
        are eligible to be included as an index participant if all of the following criteria apply:
          1. Pediatric participants or adult participants (of any age)
          2. The index participant must:
               1. Have at least 1 COVID-19 symptom within 24 hours before the index participant
                  providing informed consent. COVID-19 symptom(s) must be deemed by the
                  investigator as related to the current SARS-CoV-2 infection (not related to
                  preexisting comorbidities) or deemed as preexisting and worsened due to
                  SARS-CoV-2 infection.
               2. Must have positive SARS-CoV-2 test (a nucleic acid amplification test or antigen
                  test) from any respiratory tract specimen from a sample collected prior to
                  randomization of the participant
          3. Must have a potential study participant who can participate in the study after onset
             of COVID-19 symptoms in an index participant
        Study Participants
        Multiple study participants from the same household are allowed to be enrolled in the
        study. The study intervention randomization will be performed based at the study
        participant's level. Participants will be eligible to be included in the study only if all
        of the following criteria apply:
          1. ≥ 12 years of age at the time of signing the informed consent
          2. Has a negative screening for SARS-CoV-2 infection, as determined by SARS-CoV-2 test (a
             nucleic acid amplification test or antigen test) from any respiratory tract specimen
             (for example, oropharyngeal, nasopharyngeal or nasal swab, or saliva).
          3. Has lived in household with index participant and will continue to live in same
             household and share common areas such as dining rooms and bathrooms until the end of
             the study
          4. Must not be considered by the investigator or subinvestigator to have SARS-CoV-2
             infection and:
               1. No measured fever at Screening (defined as body temperature ≥ 38.0°Celsius [C]
                  per tympanic or rectal thermometer or ≥ 37.5°C per axillary, oral, or
                  forehead/temporal thermometer)
               2. No COVID-19 symptoms at Screening (if a participant has COVID-19-like symptoms
                  caused by comorbidities, only 1 symptom will be allowed)
          5. Capable and willing to complete a participant diary
          6. a. Male participants: Participants with partners that are woman of childbearing
             potential (WOCBP) must agree to use effective contraception. Participants with
             pregnant partners must agree to use effective contraception.
             b. Female participants: A female participant is eligible to participate if she is not
             pregnant or breastfeeding, and the following conditions applies:
               -  Is not a WOCBP or
               -  All of the following apply:
                    -  Is a WOCBP and using a contraceptive method that is effective as described
                       in the protocol.
                    -  A WOCBP must have a negative urine pregnancy test within 24 hours before the
                       first dose of study intervention period.
                    -  If a urine pregnancy test cannot be confirmed as negative (for example, an
                       ambiguous result), a serum pregnancy test must be negative.
               -  Additional requirements for pregnancy testing during and after study intervention
                  as described in the protocol.
               -  The investigator/subinvestigator will review medical history, menstrual history,
                  and recent sexual activity to decrease the risk of inclusion of a woman with an
                  early undetected pregnancy.
          7. Participant must be randomized ≤ 72 hours from onset of COVID-19 symptoms in the index
             participant.
        Exclusion Criteria:
        Study Participants: Participants will be excluded from the study if any of the following
        criteria apply:
          1. Tested positive for SARS-CoV-2 in the past 6 months.
          2. Have an underlying disease requiring systemic corticosteroids (excluding topical),
             antipyretics/analgesics, or immunosuppressive agents.
          3. Known current renal impairment defined as creatinine clearance < 30 milliliters/minute
             by Cockcroft Gault or requiring dialysis.
          4. Participants with severe liver dysfunction, such as known history of cirrhosis or
             liver decompensation (including ascites, variceal bleeding, or hepatic
             encephalopathy).
          5. Received approved, authorized, or investigational convalescent plasma, or other anti-
             SARS-CoV-2 biologic products within 3 months of the Screening Visit
          6. Received approved, authorized, or investigational anti-SARS-CoV-2 monoclonal
             antibodies (mAbs) in the last 6 months.
          7. Received any SARS-CoV-2 vaccine within 6 months prior to the Screening Visit or is
             expected to receive a SARS-CoV-2 vaccine or other approved, authorized, or
             investigational postexposure prophylaxis treatments until the end of the study.
          8. Participants who have used any of the following drugs within 14 days prior to
             enrollment:
               1. Strong cytochrome P450 (CYP) 3A inducer
               2. Products containing St. John's wort
          9. Exposed to an investigational drug within 30 days or 5 half-lives of the drug prior to
             the Screening Visit.
         10. Positive urine pregnancy test at Screening Visit or are lactating.
         11. Known allergy/sensitivity or any hypersensitivity to components of S-217622 or placebo
             for S-217622.
         12. Any condition or circumstance that, in the opinion of the investigator or
             subinvestigator, would compromise the safety of the participant or the quality of the
             study data.
        Note: Other protocol-defined Inclusion/Exclusion criteria may apply.

Study details

SARS-CoV-2 Infection

NCT05897541

Shionogi

15 April 2024

Step 1 Get in touch with the nearest study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

FAQs

Learn more about clinical trials

What is a clinical trial?

A clinical trial is a study designed to test specific interventions or treatments' effectiveness and safety, paving the way for new, innovative healthcare solutions.

Why should I take part in a clinical trial?

Participating in a clinical trial provides early access to potentially effective treatments and directly contributes to the healthcare advancements that benefit us all.

How long does a clinical trial take place?

The duration of clinical trials varies. Some trials last weeks, some years, depending on the phase and intention of the trial.

Do I get compensated for taking part in clinical trials?

Compensation varies per trial. Some offer payment or reimbursement for time and travel, while others may not.

How safe are clinical trials?

Clinical trials follow strict ethical guidelines and protocols to safeguard participants' health. They are closely monitored and safety reviewed regularly.
Add a private note
  • abc Select a piece of text.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.